VS 024
Alternative Names: VS-024Latest Information Update: 14 Dec 2021
Price :
$50 *
At a glance
- Originator University of Florida Research Foundation
- Developer Nuvara Therapeutics
- Class Amino acids; Antibronchitics
- Mechanism of Action Epithelial sodium channel modulators; Mucin modulators; Solute carrier protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 14 Dec 2021 Nuvara Therapeutics plans preclinical studies in first animal model for chronic obstructive pulmonary disease in USA in 2023 (Nuvara Therapeutics pipeline, December 2021)
- 14 Dec 2021 Nuvara Therapeutics plans preclinical studies in second animal model for chronic obstructive pulmonary disease in USA in 2024 (Nuvara Therapeutics pipeline, December 2021)
- 01 Jan 2021 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route) (Nuvara Therapeutics pipeline, December 2021)